OncoTalks | Oncology Insights at Your Fingertips

In the final installment, Dr. Luke Fletcher shares strategies for managing resistant chronic myeloid leukemia (CML), including adverse event monitoring, supportive care, and response-based dose optimization to improve long-term treatment success.
This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Luke Fletcher discusses mutation testing in chronic myeloid leukemia (CML), including when to test, how results influence treatment decisions, and the clinical significance of mutations such as T315I.
This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Luke Fletcher examines the growing role of measurable residual disease (MRD) and molecular response in treatment monitoring, and the impact of tyrosine kinase inhibitor (TKI) selection on achieving deep and durable responses for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Luke Fletcher reviews the evolving treatment approach for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), highlighting how tyrosine kinase inhibitors (TKIs) are integrated throughout induction, consolidation, and maintenance therapy to support long-term disease control.
This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Edward Pearson explores the latest advancement in anti-CD38 therapy: subcutaneous delivery of isatuximab via on-body injector. He reviews clinical evidence on efficacy, safety, and patient preference, and shares how he anticipates this innovation to impact clinic workflows, care teams, and the overall multiple myeloma patient experience.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Brook Cox, BSN, RN, OCN, an oncology nurse and infusion room supervisor, shares how subcutaneous administration of anti-CD38 therapy has transformed infusion center operations, improved patient flow, and created both opportunities and challenges for nursing teams caring for patients with multiple myeloma.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Edward Pearson reviews pivotal clinical trial data supporting anti-CD38-based regimens and explores how clinicians can balance efficacy, tolerability, and quality of life when managing high-risk and transplant-ineligible multiple myeloma.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Edward Pearson discusses the growing role of anti-CD38-based quadruplet therapy and key considerations influencing frontline therapy selection for patients with newly diagnosed, transplant-ineligible multiple myeloma.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

This learning module provides a brief overview of HER2 testing in metastatic non-small cell lung, bladder, rectal, cervical, biliary tract, ovarian, pancreatic, endometrial, and colon cancers, highlighting disease-specific testing approaches, interpretation of HER2 results, and key dosing and safety monitoring considerations.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, Dr. Yair Levy shares his approach to BTKi selection for patients with chronic lymphocytic leukemia (CLL), highlighting the growing role of second-generation BTK inhibitors, and the importance of tailoring treatment to individual patient characteristics. The discussion also explores the challenges providers face when navigating insurance requirements, medication access, and long-term adherence. Learn how thoughtful treatment selection and patient-centered education can help improve outcomes throughout the CLL treatment journey.
Listen to Navigating the CLL Treatment Landscape: The Role of Physician Choice as Dr. Levy discusses why preserving physician autonomy is essential to delivering optimal, patient-centered oncology care.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.